tbuckley/cabot-search huggingface dataset:
P1-14-01: Randomized Phase II Trial of Weekly vs. q 2-Weekly vs. q 3-Weekly Nanoparticle Albumin-Bound Paclitaxel with Bevacizumab as First-Line Therapy for Metastatic Breast Cancer.
Authors: AD Seidman, AK Conlin, A Bach, A Forero-Torres, G Wright, MH Hackney, A Clawson, D Schofield, J Iglesias, CA Hudis
Journal: Cancer Research (2011)

Abstract Background: Nanoparticle albumin-bound paclitaxel (nab-P) 260 mg/m2 is superior to paclitaxel 175 mg/m2 (P) every 3 weeks (Gradishar et al. JCO 2005) in metastatic breast cancer (MBC), and weekly uninterrupted P is more effective than q3wk P in MBC (Seidman et al. JCO 2008). Bevacizumab (bev) nearly doubles response rate and time to progression (TTP) when added to P as 1st line therapy for MBC (Miller et al. NEJM 2007). Methods: This open-label, phase II study randomized patients (pts) to nab-P at 260 mg/m2 q3wk (arm A) vs. 260 mg/m2 q 2wk with filgrastim (arm B) vs. 130 mg/m2 weekly uninterrupted (arm C), all with bev (15 mg/kg q 3 weeks arm A, 10 mg/kg q 2 weeks arms B and C). Patients were required to have measurable, HER2 negative MBC and no prior chemotherapy for MBC. The primary endpoints were response rate and toxicity. Results: Of 212 pts randomized, 208 (75 arm A, 54 arm B, 79 arm C) were treated, with balanced demographics and baseline characteristics. The median age was 57 (range 29–85), 82% were postmenopausal and 89% had visceral disease (64% lung, 50% liver). ECOG PS 0:60%, 1:35%, 2:5%. 62% had prior neo-adjuvant or adjuvant chemotherapy for early stage disease: anthracycline: 54%, taxane: 38%. No significant differences in confirmed complete and partial response rates were noted (A: 40%, B: 44%, C: 46%). Median TTP was longer in Arm C (9.0 months) versus both arms B (6.3 months) and A (8.0 months), overall p=0.065. There were no differences in overall survival (Arm A: 21.3 months, Arm B: 19 months, Arm C: 25.3 months). As per protocol-specified stopping rule, arm B was closed early due to an unacceptable safety profile with significantly more grade ≥ 2 fatigue (B:57%, A: 39%, C:39%, p=0.048) and bone pain (B:19%, A:10%, C:4%, p=0.024). Sensory neuropathy was common; grades 2/3/4: Arm A: 29%/32%/1%, Arm B: 15%/50%/2%, Arm C: 27%/43%/1%). Sensory neuropathy was commonly readily reversible with dose delay and reduction. Febrile neutropenia occurred in &amp;lt;2% of pts in all arms. Arm C patients experienced significantly less arthralgia compared with arms A and B, but dose delays were frequent (86% of pts) on this planned uninterrupted weekly schedule. Bevacizumab-related events were consistent with prior phase III trials of taxane/bev; there were no new safety signals. Conclusions: Significant and similar antitumor activity was observed in all arms. Weekly nab-P with bev (arm C) resulted in longer TTP. Weekly nab-P with bev (arm C) appears to have the highest therapeutic index, however sensory neuropathy is limiting, suggesting that a 3 week on/1 week off schedule could be preferable and should be studied comparatively. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-14-01.
Multidrug Resistance in Plague
Authors: David T. Dennis, James M. Hughes
Journal: New England Journal of Medicine (1997)

Untreated, human plague is often fulminant and fatal,1 which reinforces its historical reputation as a devastating disease. Plague is a zoonosis of rodents and their fleas caused by Yersinia pestis, a member of the family Enterobacteriaceae. People are usually infected by bites from fleas found on rodents, occasionally by direct contact with infectious tissues or exudates, and rarely by respiratory droplets from a person or animal with pneumonic plague. Distinct foci of rodent plague are widely distributed in temperate and tropical areas of the world,2 resulting each year in both sporadic cases and outbreaks of human plague. From 1980 through . . .
837 PREDICTION OF RESPONSE TO PEG-IFN/RBV THERAPY FOR CHRONIC HEPATITIS C GENOTYPE 2a AND 2b WITH HIGH VIRAL LOAD
Authors: S.R. Kim, A. El-Shamy, I. Shoji, S. Imoto, K.I. Kim, Y. Tanaka, T. Hatae, Y. Hasegawa, A. Fujinami, M. Ohta, H. Hotta
Journal: Journal of Hepatology (2013)
PWE-057 Bilateral reversal of a virtual lesion to human pharyngeal motor cortex by carbonated water swallowing: Abstract PWE-057 Figure 1
Authors: O Elshukri, H Mentz, S Hamdy, S Mistry, E Michou
Journal: Gut (2012)

<h3>Introduction</h3> Anecdotal clinical evidence supports the use of carbonated liquids in reducing the likelihood of aspiration in dysphagic patients (Bulow <i>et al. Acta Radiol</i> 2003; Sdravou <i>et al. Dysphagia</i> 2011). Repetitive transcranial magnetic stimulation (rTMS) delivered at 1-Hz can induce transient focal suppression of pharyngeal motor cortex (Mistry S, <i>et al. J Physiol</i> 2007). Here we investigated whether swallowing of carbonated water can reverse the inhibitory effects of a virtual lesion to pharyngeal motor cortex, compared to still water and saliva swallowing. <h3>Methods</h3> In 14 healthy subjects (7 male, mean age 34±15 (SD)) pharyngeal electromyographic responses were recorded using an intraluminal catheter after the application of Transcranial Magnetic Stimulation (TMS) over pharyngeal motor cortex, as a measure of cortico-bulbar excitability. On three randomised visits, subjects were cued by a visual feedback software to perform a total of 40 swallows over 10 min (swallows every 15 s) of either carbonated water or still water vs 10 min of saliva swallowing ad libitum (control), before and after an unilateral 1-Hz virtual lesion of the pharyngeal motor cortex. Cortical excitability (presented as mean±SEM) was then reassessed bilaterally for 60 min post-interventions and analysed with repeated measures ANOVA (SPSS V.14). <h3>Results</h3> A three-way ANOVA showed a significant interaction of Hemisphere × Intervention × Time [F(1,13)=5.82, p=0.03]. Compared to saliva swallowing (control), there was significant increase in cortical excitability bilaterally following swallowing of carbonated water (lesioned pharyngeal motor cortex [F(1,13)=7.5, p=0.017], with a maximum increase of 81±38% at 30 min post intervention (Abstract PWE-057 figure 1A); unlesioned [F(1,13)=4.75, p=0.04], with a maximum of 46±16%, immediately post intervention, Abstract PWE-057 figure 1B), not seen with still water swallowing. <h3>Conclusion</h3> Carbonation reverses the effects of a unilateral virtual lesion with significant increases in cortical excitability not limited to the lesioned hemisphere. These data support the notion that chemesthetic stimuli of carbonation may provide the required peripheral sensory information that can influence brain swallowing activity compared to still water swallowing. These data provides the platform for considering the use of carbonation as facilitating stimuli in dysphagic patients who aspirate thin liquids. <h3>Competing interests</h3> None declared.
AB0488 Nailfold videocapillaroscopy and laser speckle contrast analysis: in search of a correlation between microvascular damage and blood perfusion.
Authors: B. Ruaro, A. Sulli, E. Bernero, F. Ravera, C. Pizzorni, B. Seriolo, M. Cutolo
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Microvascular impairment and decreased peripheral blood perfusion are typical aspects of systemic sclerosis (SSc) (1,2). It is not clear if there is a correlation between nailfold microangiopathy and blood perfusion (BP) in different skin areas of the body in SSc patients. <h3>Objectives</h3> The aim of this study was to identify, in SSc patients, possible correlations between nailfold microangiopathy extent and BP degree in three different body areas (periungual, dorsum of hand and zygoma). <h3>Methods</h3> Fifty SSc patients (mean age 57±10SD years) were enrolled after written informed consent. All patients were assessed by nailfold videocapillaroscopy (NVC) to assess the proper pattern of microvascular damage ("early", "active", or "late"), and calculate the microangiopathy evolution score (MES) (3-5). BP was analysed by the new technique laser speckle contrast analysis (LASCA) by creating regions of interest (ROIs) at the periungual areas of the fingers, dorsum of hands and zygomas bilaterally: the average perfusion was scored as perfusion units (PU) (6). Patients enrolled into the study were not taking vasoactive drugs since at least one month before LASCA assessment. Non-parametric tests were used for the statistical analysis. <h3>Results</h3> A statistically significant progressive decrease of BP was observed by LASCA in SSc patients with different "early", "active", or "late" NVC pattern of microangiopathy at the level of periungual areas (p&lt;0.001). No statistically significant difference was observed between the three NVC patterns and BP at the level of both dorsum of hands and zygomas. A significant negative correlation was confirmed between MES and BP at periungual area (r=-0.48, p&lt;0.0001). On the contrary, no statistically significant correlation was found between MES and BP at the level of both dorsum of hands and zygomas. <h3>Conclusions</h3> A significant correlation between nailfold microangiopathy extent (evaluated by NVC) and BP degree (evaluated by LASCA) seems to exist in SSc patients at the periungual level, but not at dorsum of hands and zygomas. <h3>References</h3> Cutolo M, et al. Nat Rev Rheumatol 2010; 6, 578-87. Murray AK, et al. Arthritis Rheum 2006; 54: 1952-60. Sulli A, et al Arthritis Rheum. 2012; 64: 821-5. Sulli A, et al. Ann Rheum Dis 2008; 67:885-7. Smith V, et al. Ann Rheum Dis 2010; 69:1092-6. Draijer M et al. Laser Med Sci 2009; 24: 639-51. <h3>Disclosure of Interest</h3> None Declared
Letter to the Editor: Smoking and older age associated with mumps in an outbreak in a group of highly-vaccinated individuals attending a youth club party, the Netherlands, 2012
Authors: J Hassan, M Carr, J Connell, C De Gascun
Journal: Eurosurveillance (2014)

Preview this article: Letter to the Editor: Smoking and older age associated with mumps in an outbreak in a group of highly-vaccinated individuals attending a youth club party, the Netherlands, 2012, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/19/20/art20807-en-1.gif
Repeated Nephrotic Episodes with Normal Urine, Serum Protein and Cholesterol in the Edema-Free Intervals
Authors: Harry A. Derow
Journal: New England Journal of Medicine (1949)

A PATIENT in whom the nephrotic syndrome appeared and disappeared on three occasions has been observed from 1933 to 1948. During each remission albuminuria and edema disappeared, and the serum protein and cholesterol values returned to normal. Only 3 similar cases have been located in the extensive literature on the subject. The details of this case including the many observations made over the period of fifteen years and a review of the relevant literature are the subject of this report.Case ReportM. C (B.I.H. No. 18029), a 17-year-old boy, entered the hospital on April 17, 1933, because of swelling . . .
The Teratogenicity of Anticonvulsant Drugs
Authors: Lewis B. Holmes, Elizabeth A. Harvey, Brent A. Coull, Kelly B. Huntington, Shahram Khoshbin, Ailish M. Hayes, Louise M. Ryan
Journal: New England Journal of Medicine (2001)

The frequency of major malformations, growth retardation, and hypoplasia of the midface and fingers, known as anticonvulsant embryopathy, is increased in infants exposed to anticonvulsant drugs in utero. However, whether the abnormalities are caused by the maternal epilepsy itself or by exposure to anticonvulsant drugs is not known.
A simple ex vivo pig stomach model for learning endoscopic submucosal dissection
Authors: Nicolás González, Klaus Mönkemüller, C. Wilcox, Andrés Taullard, Miguel Villa-Gómez, Adolfo Parra-Blanco
Journal: Endoscopy (2014)

Endoscopic submucosal dissection (ESD) is an accepted technique for the resection of early neoplasia of the luminal gastrointestinal tract. ESD is a routine procedure in many Asian countries [1], however, its utility is now being recognized worldwide [2]. It is an advanced endoscopic technique with a steep learning curve [3]. Training in animal models is thought to improve technical skills and result in a rapid progression in the learning process for various advanced endoscopic procedures including endoscopic retrograde cholangiopancreatography, hemostasis, endoscopic mucosal resection, and ESD [4]. Most models used at the present time are not widely available and are cumbersome to use. Herein we present an ex vivo pig stomach model which we have used to perform ESD and other advanced endoscopic procedures ([Fig. 1]). [Video 1] shows the key aspects of this model. A hole is made in one of the sides of a plastic box and a syringe is placed in the hole and used to simulate the mouth and esophagus (a "pseudoesophagus"). The pig's stomach placed inside the box is then attached to the syringe using a zip tie and sutures through which the scope and ESD accessories are introduced. Target lesions for resection are produced and the ESD procedure is conducted according to established standards. We recommend that, at an initial stage, the basic movements and techniques of ESD should be learned in ex vivo models, as these are potentially widely available, inexpensive, and mimic human anatomy reliably [5].
Dramatic transient improvement of metastatic BRAFV600E-mutated Langerhans cell sarcoma under treatment with dabrafenib
Authors: Samia Mourah, Gwenaël Lorillon, Véronique Meignin, Laetitia Vercellino, Constance de Margerie-Mellon, Cécile Pages, Lauriane Goldwirt, Alexandre How-Kit, Jorg Tost, Céleste Lebbe, Abdellatif Tazi
Journal: Blood (2015)
Abstract C40: Recombinant viral protein suppresses metastasis of ovarian adenocarcinoma cells through negative Akt signaling
Authors: Jei-Ming Peng, Shao-Wen Hung, Ching-Feng Chiu, Ming-Yi Ho, Michael Hsiao, Chi-Ming Liang, Shu-Mei Liang
Journal: Cancer Research (2011)

Abstract Ovarian cancer has a high fatality rate, mainly due to metastatic progression of tumor cells. Advances in the treatment of metastatic ovarian cancer are needed. Here, we studied the mechanism of action of a recombinant viral capsid protein (rVP1) and explored its effect against ovarian tumor growth and metastasis in vivo. We found that rVP1 was cytotoxic to several human ovarian cancer cell lines, namely doxorubicin-resistant SKOV3, cisplatin-resistant OVCAR-3, and TOV-21G. rVP1 was more potent than doxorubicin and cisplatin in inducing apoptosis and inhibiting growth of SKOV3 in vitro. Treatment of SKOV3 or peritoneal adapted SKOV3ip.1 cells with rVP1 at certain concentrations below IC50 resulted mainly in inhibition of cell invasion rather than apoptosis. This inhibitory effect of rVP1 on cell invasion was accompanied with activation of PTEN and GSK-3β as well as downregulation of FAK, Akt and MMP-2. Anti-integrin antibodies or overexpression of constitutively active Akt reversed the cellular effects of rVP1. In vivo studies confirmed that rVP1 attenuated survival and metastasis of SKOV3 cells through the selective regulation of Akt and GSK-3β activity in an orthotopic xenograft mouse model as revealed by bioluminescence imaging of mice and immunohistological analysis. In addition, rVP1 decreased the formation of ascites and metastatic tumor nodules formed by SKOV3 cells in an intraperitoneal xenograft mouse model. These results indicate that negative regulation of Akt signaling by rVP1 may have the potential to suppress ovarian tumor growth and metastasis in vivo. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr C40.
FRI0125 Impact of Repeating Imaging of the Sacro-Iliac Joints over One Year on the Classification According the ASAS Axial SPA Criteria of Patients
Authors: P. Bakker, M. de Hooge, R. van den Berg, F. van Gaalen, M. Reijnierse, T. Huizinga, D. van der Heijde
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> It is known that in axial spondyloarthritis (axSpA) inflammatory lesions on MRI of the SI joints (MRI-SI) can change over time. The usefulness of repeating imaging in the diagnostic process is unclear. <h3>Objectives</h3> To investigate how patients with short-term chronic back pain are classified by the ASAS axSpA- criteria at baseline and after 1 year follow-up, with a focus on the role of imaging. <h3>Methods</h3> Patients in the SPACE cohort (back pain: ≥3 months, ≤2 years, onset &lt;45 years) with (suspicion of) axSpA underwent MRI and X-rays of the sacroiliac joints at baseline and 1 year follow-up. Only patients with complete MRI- and X-SI data at both baseline and year 1 were included in the analysis (n=80). MRI-SI and X-SI were scored independently by 3 well-calibrated readers according to the ASAS definition for a positive MRI and the mNY-criteria. Readers were blinded for patient characteristics and time sequence. Fulfillment of ASAS or mNY criteria was considered positive if 2/3 readers agreed. For each timepoint, patients were classified according the ASAS axSpA criteria and grouped in different arms (imaging arm: mNY+/- or MRI+/-; clinical arm, fulfillment of both arms and possible axSpA). In contrary to the normal application of the criteria, where a positive feature remains positive, we grouped patients according to the finding at one year, ignoring previous imaging findings. <h3>Results</h3> At baseline, 41/80 patients (32.8%) fulfilled the ASAS criteria (clinical arm: 22; imaging arm: 12, both arms: 7) (table). After 1 year, 3 additional patients fulfilled the criteria (2 clinical arm; 1 imaging arm). After 1 year, in 5 patients MRI-SI became positive and 1 patient fulfilled the mNY criteria. On the other hand, MRI-SI became negative after 1 year in 4 other patients. Of these patients, 3 still fulfilled the ASAS criteria (imaging arm (mNY+, n=1) or clinical arm (n=2)). Only 1 patient (classified as axSpA at baseline) would be missed if imaging would have been performed at 1 year only (due to a negative MRI). <h3>Conclusions</h3> With one year longer symptom duration, 3/39 (8%) of the possible SpA patients could be classified additionally as axSpA because of additional SpA features (5%) or positive MRI (3%), while 1/41 (2%) of the axSpA patients would not be classified due to a normal MRI. There was a switch between imaging and clinical arm in 12% of the patients. Therefore, our data show the robustness of the axSpA criteria and does not support repeating imaging after one year. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1630
Case 27-2013
Authors: Shuba R. Iyengar, David H. Ebb, Qian Yuan, Randheer Shailam, Atul K. Bhan
Journal: New England Journal of Medicine (2013)

A 6.5-month-old boy was admitted to the hospital because of thrombocytopenia. Anti-D immune globulin was administered intravenously, with improvement, but thrombocytopenia recurred, with anemia and neutropenia, and food allergies developed. Diagnostic tests were performed.
AB1159 Certolizumab in juvenile idiopathic arthritis (JIA): Experience of 12 patients treated
Authors: I. Pontikaki, M. Gattinara, C. Donati, P.L. Meroni, V. Gerloni
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Biological agents have demonstrated a favourable benefit-to-risk profile. Nevertheless, intolerance, lost of efficacy or adverse events has led to try other therapeutic options as the use of new TNF-inibithors. Since november '99 to dicembre 2011, 288 patients affected by refractory JIA were treated with TNF inhibitors. <h3>Objectives</h3> To evaluate in a single pilot study efficacy and safety of Certolizumab in JIA with active polyartritis, non responders to MTX, antiTNF, anti CD20 and anti-IL-1. <h3>Methods</h3> During the last 8 months we have switched to Certolizumab 12 young adults (8 F, 4 M) non responders to the older biological agents. Two patients had a Systemic onset of JIA, 3 polyarthritis RF negative, 2 oligoarthritis persistent and 5 oligoarthritis extended. Median age 23.5 yrs, median onset age 7.7 yrs, median disease duration 17.7 yrs. All patients had active disease; three of them had active uveitis as well. Patients received Certolizumab at the dose of 400 mg s.c. at week 0, 2, 4 and 200 mg every other week, as in RA. All patients had failed more previous DMARDS (as MTX, Ciclosporin, Chlorambucil, gold therapy), and TNF inhibitors (Infliximab, Etanercept, Adalimumab), Rituximab and Anakinra. <h3>Results</h3> All patients were evaluated according to EULAR criteria (DAS 28). No serious adverse events were observed. Eight patients (66.6%) were responders, 4 patients (33.3%) were non responders (3 of them =25% droped-out). Two patients out of 3 with chronic active uveitis showed a visus improvement. <h3>Conclusions</h3> Certolizumab could be another new treatment of long lasting refractory JIA (including cases complicated by uveitis), in young adults non responders to the previous generation of antiTNF. In our knowledge, this is one of the first experiences in the use of Certolizumab in young adults affected by JIA. <h3>Disclosure of Interest</h3> None Declared
PTH-011 Changing Trends Of Ercp, A Decade Apart
Authors: K Hameed
Journal: Gut (2014)

<h3>Introduction</h3> ERCP has become a well established therapeutic intervention. Indications and practice of ERCP have changed over the years due to advent of new imaging modalities. Our aim was to evaluate the ERCP indications, diagnosis and complications over 12month period, a decade apart. <h3>Methods</h3> Retrospective observational audit, data extracted from endoscopy reporting system and electronic patient’s records. Consecutive patients undergoing ERCP over 12 months in 2002 and 2012. <h3>Results</h3> Total number of ERCP’s performed was 233 and 212 in the year 2012 and 2002. Median age was 73 and 69 with IQR (58–82) and (56–80) years respectively. Gender ratio in 2012 of 1:1.1 and 1:1.5 in 2002. Diagnosis: in year 2012: stone disease 109 (46%). Pancreatic Cancer 31 (13.7%). Normal biliary tree 22(9%)whilst in the year In the year 2002 stone disease 90(42%). Pancreatic Cancer 16(7.5%). Normal Biliarytree 60(28%). Interventions: Year 2012: stent insertion 72(30.9%) and sphincterotomy 155(66.5%). year 2002 stent insertion 39(18.3%) and sphincterotomies 86(40.6%). Technical success rate in both the years was 95%. Complications: 30 day mortality in 2012 was 22(9.4%)and 12(5.7%) in 2002. There was one procedure related death in year 2012 (0.4%), none in 2002. Bleeding requiring transfusion : 14(6%) in 2012 6(2.6%) in 2002. Pancreatitis 6(2.6%) and 6(3.3%) in 2012 and 2002. Seven patients required sedation reversal in year 2002 as opposed to 0 in 2012. Reflecting the significantly reduced doses being used in the latter year. <h3>Conclusion</h3> 1) Work load remained the same. 2) Less number of normal ERCP’S 3) More pancreatic malignancies identified 4) More therapeutic procedures undertaken. <h3>Disclosure of Interest</h3> None Declared.
Gut microbiota and protection from pneumococcal pneumonia
Authors: Robert P Dickson, Michael J Cox
Journal: Gut (2016)

Dear Editor,

We read with interest the work by Schuijt et al 1 reporting that sustained treatment with broad-spectrum antibiotics increases the susceptibility of mice to pneumococcal pneumonia, an effect that is reversed via faecal microbiota transplantation (FMT). Yet we question the authors' confidence that this effect is entirely attributable to alterations in …
Anionic Dyes, Heparin, and Heparinoids: The Rediscovery of Polyanionic Tumor Inhibitors
Authors: W. REGELSON
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Anionic Dyes, Heparin, and Heparinoids: The Rediscovery of Polyanionic Tumor Inhibitors Get access WILLIAM REGELSON WILLIAM REGELSON Medical College of Virginia, Virginia Commonwealth UniversityPO Box 273, Richmond, VA 23298 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 24, 20 December 1989, Pages 1929–1930, https://doi.org/10.1093/jnci/81.24.1929 Published: 20 December 1989